Tango Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026Board expansion and new director appointment signal governance changes affecting company leadership and decision-making.
Large capital raise provides cash for operations, clinical trials, and growth, diluting existing shareholders.
Stock pricing at $30 reflects investor demand and provides funds; warrants give buyers future purchase options.
Early prospectus filing starts formal process for raising capital through public stock sale.
92% response rate in pancreatic cancer trials demonstrates drug effectiveness, potentially supporting future approvals.
Annual meeting is where shareholders make key decisions about company leadership and policies.
Director departures change board composition; Sung Lee becomes Lead Independent Director and committee chair.
Stocky reads Tango Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Tango Therapeutics, Inc.'s most recent tracked filing was a 8-K on 23 Jun 2026: Robert Azelby joins board as seventh director.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.